Massive Coverup Attempt About Origins Of Omicron Variant And Seriousness Of The New Variant By Those Controlling The COVID-19 Narratives. Exclusive Expose Soon To be Published.

BREAKING NEWS
Source: SARS-CoV-2 A.30 Variant  Oct 27, 2021  1 month ago
BREAKING! German Research Reveals That New SARS-CoV-2 Variant A.30 Is Almost Totally Evasive To Antibodies Generated By Current Vaccines!
BREAKING! German Research Reveals That New SARS-CoV-2 Variant A.30 Is Almost Totally Evasive To Antibodies Generated By Current Vaccines!
Source: SARS-CoV-2 A.30 Variant  Oct 27, 2021  1 month ago
SARS-CoV-2 A.30 Variant: German researchers from Georg-August-University Göttingen, the German Primate Center, Friedrich-Alexander University of Erlangen-Nürnberg and Hannover Medical School have found in that the newly emerging SARS-CoV-2 variant A.30 is almost totally evasive to antibodies generated by current COVID-19 vaccines!

 
The study findings were published in the peer reviewed journal: Cellular And Molecular Immunology By Nature. https://www.nature.com/articles/s41423-021-00779-5
 
Although the A.30 variant (Also known as A.VOI.V2), which likely originated in Tanzania and was later detected in several patients in Angola and Sweden in February 2021 has been not been able to become dominant in circulation as a result of being displaced by the more transmissible Delta variant and its sub-variants, it along with the other worrisome variants like the Mu variant, Lambda variant and the R.1 variant are not totally out of existence yet as they have still been popping up in sequencings. Caution and constant surveillance is still needed as they can easily evolve to gain viral fitness and enhanced transmissibility or even recombine with a delta variant or sub-variant.
 
The current COVID-19 pandemic, caused by the pathogen SARS-CoV-2, continues to wreak havoc in many countries, straining health systems and economies. Vaccines protect against severe disease and death and are considered by many so called ‘experts’ from the West as key to ending the pandemic. COVID-19 vaccines (and SARS-CoV-2 infection) elicit antibodies that are directed against the viral spike (S) protein and neutralize the virus.

Alarmingly, the emergence of SARS-CoV-2 variants with S protein mutations that confer resistance to neutralization might compromise vaccine efficacy. Furthermore, emerging viral variants with enhanced transmissibility, likely due to altered virus-host cell interactions, might rapidly spread globally.

The SARS-CoV-2 A.30 Variant study team investigated host cell entry and antibody-mediated neutralization of the variant A.30.

For comparison purposes, the study team analyzed the Beta (B.1.351) and Eta (B.1.525) variants. These two variants were first detected in Africa, and the Beta variant, which is considered a variant of concern (VOC), shows the highest level of neutralization resistance among SARS-CoV-2 VOCs.

When compared to the S protein of SARS-CoV-2 B.1, which circulated in the early phase of the pandemic, the S protein of the A.30 variant contains 10 amino acid substitutions and five deletions.

All deletions along with four substitutions are found in the N-terminal domain of the surface unit S1, which harbors an antigenic supersite that is targeted by most neutralizing antibodies not directed against the receptor-binding domain (RBD).

Furthermore, three mutations are located inside the RBD, which binds to the cellular receptor ACE2 and constitutes the main target of neutralizing antibodies.


#A9A9A9">SARS-CoV-2 A.30 enters certain cell lines with increased efficiency and evades antibody-mediated neutralization. a Schematic overview and domain organization of the SARS-CoV-2 S proteins studied. Abbreviations: RBD, receptor-binding domain; TD, transmembrane domain. b Pseudotyped particles bearing the indicated S proteins were inoculated onto different cell lines, and transduction efficiency was quantified by measuring virus-encoded luciferase activity in cell lysates at 16–18 h postinoculation. Presented are the average (mean) data from six to 12 biological replicates (each conducted with technical quadruplicates) for which transduction was normalized against SARS-CoV-2 S B.1 (= 1). Error bars indicate the standard error of the mean (SEM). The statistical significance of differences between B.1 and A.30, B.1.525, or B.1.351 was analyzed by two-tailed Student’s t-test with Welch correction (p > 0.05, not significant [ns]; p ≤ 0.05, *; p ≤ 0.01, **; p ≤ 0.001, ***). See also Supplemental information, Fig. S1b. c Neutralization of SARS-CoV-2 B.1, A.30, B.1.525, and B.1.351 by monoclonal antibodies used for COVID-19 therapy or an unrelated control antibody (Supplemental information, Fig. S1d). Pseudotyped particles were incubated for 30 min at 37 °C in the presence of increasing concentrations (0.00002, 0.0002, 0.002, 0.02, 0.2, 2 µg/ml) of the indicated monoclonal antibodies or an unrelated control antibody before being inoculated onto Vero cells. Infection efficiency was quantified by measuring virus-encoded luciferase activity in cell lysates at 16–18 h postinoculation. Presented are average (mean) data from a single biological replicate (conducted with technical quadruplicates) for which infection was normalized against samples that did not contain antibody (= 0% inhibition). The data were confirmed in a separate independent experiment. Error bars indicate the standard deviation. d Neutralization of SARS-CoV-2 B.1, A.30, B.1.525, and B.1.351 by antibodies in convalescent plasma. Pseudotyped particles bearing the indicated S proteins were incubated for 30 min in the presence of different dilutions of convalescent plasma (n = 9). Infection efficiency was determined as described for Fig. 1b and used to calculate the plasma dilution factor leading to a 50% reduction in S protein-driven cell entry (neutralizing titer 50, NT50). Data from a total of nine convalescent plasma samples are presented (black lines and numerical values indicate the median NT50). In addition, for each plasma, the fold reduction in NT50 between SARS-CoV-2 B.1 (set as 1) and the indicated variants was calculated (gray bars indicate the median). The statistical significance of differences between the indicated groups was analyzed by a two-tailed Mann–Whitney test with a 95% confidence level (p > 0.05, ns; p ≤ 0.05, *; p ≤ 0.01, **; p ≤ 0.001, ***). e The experiment was performed as described in Panel d, but serum from ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 (AZ/AZ; n = 23), BNT162b2/BNT162b2 (BNT/BNT; n = 12) or ChAdOx1 nCoV-19/BNT162b2 (AZ/BNT; n = 6)-vaccinated individuals was investigated. Numbers in the bar graphs “B.1 vs. A.30” and “B.1 vs. B.1.525” indicate the number of overlapping data points (dots)

Importantly two of these mutations, T478R and E484K, are located close to the ACE2 binding site and E484K is known to reduce susceptibility to antibody-mediated neutralization. Finally, two mutations are located close to the S1/S2 cleavage site, and one mutation is found in the transmembrane unit S2, which facilitates fusion of the viral envelope with cellular membranes.

The study findings alarmingly showed that A.30 exhibits a cell line preference not observed for other viral variants and efficiently evades neutralization by antibodies elicited by ChAdOx1 nCoV-19 or BNT162b2 vaccination.
 
The entry of SARS-CoV-2 into cell lines depends on S protein activation by the cellular proteases cathepsin L or TMPRSS2, and activation by the latter is thought to support viral spread in the lung. Therefore, it is noteworthy that enhanced A.30 entry was observed for cell lines with cathepsin L (Vero, 293 T, Huh-7, A549 cells) but not TMPRSS2 (Calu-3, Caco-2)-dependent entry.
 
Hence, one could speculate that A.30 might use cathepsin L with increased efficiency and slight (but not statistically significant) resistance of A.30 against the cathepsin L inhibitor MDL 28170 supports this possibility.
 
Significantly, robust entry into cell lines was combined with high resistance against antibodies induced upon ChAdOx1 nCoV-19 or BNT162b2 vaccination. Neutralization resistance exceeded that of the Beta (B.1.351) variant, which is markedly neutralization resistant in cell culture and, in comparison with the Alpha (B.1.1.7) variant, is less well inhibited by the ChAdOx1 nCoV-19 vaccine.
 
Nevertheless, heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination, which was previously shown to augment neutralizing antibody responses against VOCs compared to corresponding homologous vaccinations might offer robust protection against the A.30 variant.
 
The study findings suggest that the SARS-CoV-2 variant A.30 can evade control by vaccine-induced antibodies and might show an increased capacity to enter cells in a cathepsin L-dependent manner, which might particularly aid in the extrapulmonary spread. As a consequence, the potential spread of the A.30 variant warrants close monitoring and rapid installment of countermeasures.
 
For more on the SARS-CoV-2 A.30 Variant, keep on logging to Thailand Medical News.

MOST READ

Feb 05, 2020  2 years ago
Source : Thailand Medical news

FROM GENOMICS AND EPIGENETICS

LATEST ON CARDIOLOGY